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ABSTRACT
Purpose The purpose of the Danish HIV Birth Cohort 
(DHBC) is to investigate the significance of HIV-1 infection 
in pregnancy and after delivery in women living with 
HIV (WLWH) in Denmark and their children, in the era of 
antiretroviral therapy and other interventions for treatment 
and prophylaxis.
Participants All WLWH giving birth to one or more 
children in Denmark after 31 December 1999 are included, 
with consecutive ongoing enrolment, if they are living 
with HIV and pregnant, or if they are diagnosed with HIV in 
relation to pregnancy, delivery or shortly after delivery.
Findings to date DHBC has been used to describe trends 
in the management of pregnancies in WLWH and their 
outcomes on a nationwide basis, mode of delivery and 
predictors of emergency caesarean section as well as 
risk factors during pregnancy in WLWH for birth- related 
complications compared with women from the general 
population (WGP). We have found that HIV- exposed, but 
uninfected (HEU) children born to WLWH had a lower 
median birth weight and gestational age and were at 
higher risk of intrauterine growth retardation than children 
born to WGP. We have investigated risk of in- hospital 
admission and use of antibiotics during the first 4 years of 
life among HEU children and showed that HEU children had 
an increased risk of overall hospital admission compared 
with a matched control group of unexposed children.
Further, we compared anthropometric outcomes in 
children with a matched control group of children not 
exposed to HIV.
Future plans To continuously investigate the significance 
of HIV infection and antiretroviral therapy in pregnancy and 
after delivery in WLWH in Denmark and their HEU children 
and compare these findings with children born to WGP.
INTRODUCTION
The management of pregnant women living 
with HIV (WLWH) has evolved significantly, 
since the introduction of antiretroviral 
therapy (ART) for the prevention of perinatal 
transmission of HIV from mother to child.1 2 
Current recommendations include universal 
testing of pregnant women for HIV infec-
tion, immediate initiation of treatment with 
a combination of two or more antiretroviral 
drugs from at least two drug classes (combi-
nation ART (cART)), the use of caesarean 
delivery, if the mother has detectable viral 
load (VL), avoidance of breast feeding when 
feasible and post- exposure prophylaxis ART 
to the child.3–6 As cART is now recommended 
and implemented globally to all people living 
with HIV, an increasing number of WLWH 
will either conceive or initiate cART during 
pregnancy, resulting in a growing population 
of HIV- exposed, but uninfected (HEU) chil-
dren7 with exposures to HIV and cART in 
utero which in early life may have potential 
long- term adverse effects in the children.8
The Danish population consists of 
5.7 million inhabitants with an estimated 
adult HIV prevalence of 0.1%.9 10 There are 
approximately 1600 WLWH in Denmark, of 
whom 80% are of childbearing age.11 12 The 
majority of WLWH in Denmark are immi-
grants, mainly from sub- Saharan Africa, 
and primarily infected with HIV by sexual 
contact.13 We have formerly shown that the 
majority of WLWH in Denmark have few HIV- 
related symptoms, are sexually active and have 
a strong desire for children.14 The healthcare 
system in Denmark is tax- based and ensures 
universal access to both medical healthcare 
and many social support services.15 Hence, 
ART is provided free of charge and people 
Strengths and limitations of this study
 ► The Danish HIV Birth Cohort (DHBC) is based on a 
nationwide, population- based, prospective design 
including all women living with HIV (WLWH) who give 
birth in Denmark and their children.
 ► Use of the unique personal identification number as-
signed to all Danes allows us to extract data for both 
the WLWH and their children in national registries.
 ► Use of national registries ensures prospective, uni-
formly and neutral data collected on an individual 
level, restricting the methodological problems of 
loss to follow- up, selection bias and emigration.
 ► Linkage to the registries allows identification of a 
population of controls who are matched on relevant 
variables.
 ► The main limitation of the DHBC is the relatively 
small number of children born to WLWH in Denmark. 
The DHBC is thus most useful for studies with fre-
quently occurring outcomes.









pen: first published as 10.1136/bm




2 Weis N, et al. BMJ Open 2021;11:e044565. doi:10.1136/bmjopen-2020-044565
Open access 
living with HIV in Denmark are generally well treated (VL 
<50 copies/mL) with life expectancies approaching those 
of the general population.16 National antenatal screening 
for all pregnant women has been implemented as an opt- 
out programme (eg, all women are screened unless they 
decline).17 The proportion of WLWH that are diagnosed 
during pregnancy range between 18%–37%.13 18 Treat-
ment with cART has been recommended to all pregnant 
WLWH in Denmark since the late 1990s and most women 
have an undetectable VL at the time of delivery, resulting 
in a decreased risk of perinatal transmission to <1%.13 19 
Condom- less sex (without support from artificial repro-
ductive technologies) and vaginal delivery are recom-
mended in well- treated WLWH.19 20 New- born treatment 
with prophylactic antiretroviral medicine lasts for 4 weeks 
after birth.21 22
Children born to WLWH with a HIV RNA <50 copies/
mL are treated with zidovudine for 4 weeks while chil-
dren born to WLWH with a HIV RNA >50 copies/mL are 
treated with zidovudine, lamivudine and nevirapine for a 
minimum of 4 weeks.
The Danish HIV Birth Cohort (DHBC) is a nation-
wide, prospective cohort, set up to monitor the signifi-
cance of HIV in pregnancy and its outcome in children 
born to WLWH in Denmark. The cohort was set up by a 
scientific management team consisting of clinicians and 





  Date of birth
  Country of birth
  Body mass index prior to pregnancy
  HIV positive date
  Time of diagnosis in relation to 
pregnancy
  Transmission route
Maternal medical 
history
Hepatitis B and/or C infection
  Comorbidity
  AIDS diagnosis
  CD4 count at diagnosis
  HIV RNA at diagnosis
  Smoking
  Alcohol use
  Drug use
Family history Paternal HIV status
  Other children
ART treatment ART treatment prior to pregnancy
  Initiation of treatment
  Change in treatment during pregnancy
  Retrovir during labour
  Continuation of ART after delivery
  Other medications during pregnancy
Pregnancy and 
delivery
Estimated date of delivery
  Planned pregnancy
  Fertility help
  Conception
  Birth plan
  CD4 count in early pregnancy
  HIV RNA in early pregnancy
  Vitamin D in pregnancy
  Multiple/single birth
  Intrauterine growth
  Bleeding during pregnancy
  Amniocentesis
  Placenta biopsy
  Folic acid treatment
  CD4 count prior to delivery
  HIV RNA prior to delivery
  Mode of delivery
  Complications
  Pre- eclampsia
Continued
Domain Variable
  Vacuum- assistance
  Scalp lead placement
  Baby heart rate during delivery
  Artificial rupture of membranes
  pH umbilical cord
Child Date of birth
  Sex
  Birth weight
  Birth length
  Head circumference
  Apgar score
  Gestational age
  Anaemia at birth
  First objective clinical examination
  ART given to the child
  Other medications
  Breast feeding
  First HIV PCR result
  HIV status at 3, 6 and 18 months
  Transmission of HIV
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researchers from the five clinical departments of infec-
tious diseases treating pregnant WLWH in Denmark. All 
five departments are located at University Hospitals in 
four of the five regions in Denmark. Both treatment of 
HIV as well as prepartum and postpartum care are done 
in accordance with national guidelines.
The cohort is located at Copenhagen University Hospi-
tal—Hvidovre, Copenhagen, Denmark. The overall aim 
of the DHBC is to investigate the significance of HIV 
infection in pregnancy and after delivery in WLWH 
in Denmark and their children, in the era of antiretro-
viral therapy and other interventions for treatment and 
prophylaxis.
The DHBC is approved by the Danish Data Protec-
tion Agency (2012-58-0004; AHH-2017–027), the Danish 
Medical Agency (3-3013-406/4) and Center for Regional 
Development, Capital Region (R-20049159) as a clin-
ical research database with data registry in a Research 
Electronic Data Capture (REDCap) system. Individual 
consent for collection of data for research purposes 
is provided from all women included in the DHBC. 
According to Danish Law, approval from the National 
Committee on Health Research Ethics is not required as 
no biomedical intervention is performed. The national 
registries and Statistics Denmark are administered by 
national authorities.
COHORT DESCRIPTION
The DHBC is a prospective, nationwide, population- based 
cohort study including all WLWH giving birth to one or 
more children in Denmark after 31 December 1999, with 
consecutive ongoing enrolment. Women are included 
if they are living with HIV and pregnant, or if they are 
diagnosed with HIV in relation to pregnancy, delivery 
or shortly after delivery. Women who are diagnosed with 
HIV at a later time point after giving birth, when time 
of transmission cannot be determined to be prior to 
or during pregnancy are excluded. Information about 
miscarriages or stillbirths in WLWH are not included in 
the cohort. Eligible women are identified and enrolled in 
the DHBC through the clinical departments by the clini-
cians responsible for the treatment and management of 
pregnant WLWH. Hence, the risk that a woman is missed 
in the DHBC is negligible. The DHBC collects clinical 
and demographic data on both the mother and the 
child from the medical records and all data are entered 
prospectively into a REDCap database. Baseline data are 
collected the year the child was born. Annual updates are 
performed.
Baseline data are collected the year the child is born, 
including maternal demographics, maternal medical 
history, family history, cART treatment, pregnancy and 
delivery and among others on the children’s date of birth, 
sex, birth length and birth weight, head circumference, 
Apgar score, gestational age, ART, other medications, 
breast feeding and HIV transmission (table 1).
The DHBC includes 569 children born in year 2000–
2018 to 402 WLWH, including seven pairs of twins. The 
number of children born to WLWH have increased over 
time (figure 1). The demographics of the cohort are 
presented in table 2. The pregnancy was planned in a 
little more than half the women (58%, n=330), and in 
153 pregnancies (46%) it was planned together with an 
infectious disease specialist. One hundred and three 
(18%) were diagnosed with HIV during pregnancy, and 
nine women were diagnosed during birth or shortly after-
wards. Information about coinfection with hepatitis B and 
C were not available for all WLWH included in DHBC, 
but of the 402 WLWH, 28 (5%) were hepatitis B surface 
Antigen (HBsAg) positive and 129 (23%) had anti- HBs 
Figure 1 Number of 569 children born to 402 women living with HIV in Denmark and included in the Danish HIV Birth 
Cohort by year of birth and maternal treatment at delivery. InST, integrase strand transfer inhibitors; NRTI; nuklos(t)ide reverse 
transcriptase inhibitors; NNRTI, non- nuklos(t)ide reverse transcriptase inhibitors; PI, protease inhibitors; Tx: treatment.
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while 14 (2%) were hepatitis C virus (HCV- RNA) positive 
and 22 (4%) were anti- HCV positive.
Most WLWH were on cART at delivery, with the 
majority having undetectable VL at the time of delivery. 
The median gestational age was 39 weeks (IQR 38–40, 
range 24–40 weeks). Definitive exclusion of HIV infection 
of the children is based on two negative virological test 
results prior to or at 18 months of age. Perinatal transmis-
sion of HIV occurred in four children. In all these cases, 
the mother was diagnosed just prior to, during or shortly 
after delivery, and none of the four women received cART 
prior to delivery.




Maternal age at birth (mean 
(95% CI))*
32.9 (32.4 to 33.4)
  Missing 5
Country of origin (n (%))
  Danish 130 (23)
  African 327 (58)
  Asian 65 (11)
  Other 47 (8)
Comorbidity (n (%)) 144 (25)
  Unknown 35 (6)
Smoking (n (%))
  During pregnancy 67 (12)
  Former smoker 28 (5)
  Missing 46 (8)
Nulliparous (n (%)) 209 (37)
Time of maternal HIV diagnosis 
(n (%))
  Prior to pregnancy 457 (80)
  During pregnancy 103 (18)
  During/after delivery 9 (2)
Duration from diagnosis of HIV 
to delivery (years) (n (%))
5 (1–9)
Mode of HIV transmission (n (%))
  Sexual 372 (65)
  Injection drug use 17 (3)
  Other/missing 180 (32)
Antiretroviral therapy treatment 
at delivery (n (%))
  Three NRTIs 29 (5)
  Two NRTIs+NNRTI 71 (12)
  Two NRTIs+PI 356 (62)
  Two NRTIs+InST 18 (3)
  Other 89 (16)
  No treatment prior to delivery 9 (2)
Intrapartum prophylaxis (n (%)) 246 (43)
  No intrapartum prophylaxis 275 (49)
  Missing 48 (8)
CD4 cell count at delivery (n (%))
  >500 cells/µL 268 (47)
  200–499 cells/µL 237 (42)
  <200 cells/µL 25 (7)
  Missing 39 (7)




  <50 copies/mL 479 (84)
  ≥50 copies/mL 62 (11)
  Missing 28 (5)
Child characteristics†
Year of birth (n (%))
  2000–2006 161 (28)
  2007–2008 61 (11)
  2009–2016 345 (61)
Gestational age <37 weeks (n 
(%))
52 (9)
  Missing 97 (17)
Mode of delivery (n (%))
  Vaginal delivery 211 (37)
  Planned caesarean section 218 (38)
  Acute caesarean section 128 (23)
  Missing 12 (2)
Birth weight, g (mean (95% CI)) 3140.7 (3082.7 to 3197.3)
  Missing 40 (7)
Birth length, cm (mean (95%) 49.9 (49.7 to 50.3)
  Missing 75 (13)
Child sex (n (%))
  Boy 275 (48)
  Girl 261 (46)
  Missing 33 (6)
Apgar score at 10 min <7 (n (%)) 8 (1)
  Missing 23 (4)
*Number of HIV- exposed uninfected children born to 402 women 
living with HIV (WLWH).
†Children born to WLWH with HIV RNA <50 copies/mL are treated 
with zidovudine for 4 weeks while children born to WLWH with HIV 
RNA >50 copies/mL are treated with zidovudine, lamivudine and 
nevirapine for a minimum of 4 weeks.
InST, integrase strand transfer inhibitors; NNRTI, non- nuklos(t)
ide reverse transcriptase inhibitors; NRTI, nuklos(t)ide reverse 
transcriptase inhibitors; PI, protease inhibitors; Tx, treatment.
Table 2 Continued
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Using the unique 10- digit personal identification 
number (PIN), assigned to all Danish residents at birth 
(or with approved immigration status), the DHBC is 
linked to the national registries and data from Statistics 
Denmark containing medical and sociodemographic 
information on the whole Danish population.23–25 This 
data linkage allows us to capture comparison cohorts, as 
well as ascertain immigration, emigration and death.23
The DHBC has been linked to the following registries: 
the Medical Birth Registry, which contains complete 
information on all births in Denmark since 197326; the 
National Patient Registry, which contains information 
on all inpatient and outpatient hospital admissions in 
Denmark since 197727; the Danish National Prescription 
Registry, established in 1994 which contains informa-
tion on all redeemed prescriptions dispensed in Danish 
Community Pharmacies on an individual level28; the Chil-
dren’s Database, which contains all height and weight 
measurements recorded by medical doctors and nurses 
during the annual preventive health checks offered to all 
Danish children until school year 7,29 and the sociode-
mographic registries at Statistics Denmark. Data from the 
national registries and Statistics Denmark are anonymised 
and accessed through a remote connection to a server at 
Statistics Denmark.25
Patient and public involvement
Patients or the public were not involved in the design, 
conduct, reporting or dissemination plans of our research.
Findings to date
In 2010 DHBC data were used to describe trends in 
the management of pregnancies in WLWH and their 
outcomes on a national basis.19 The annual number of 
HIV pregnancies increased significantly during the study 
period and substantial changes in pregnancy manage-
ment were seen. No perinatal transmissions occurred in 
WLWH, who received treatment according to the national 
guidelines at that time, that is, cART before week 22, 
intravenous zidovudine (ZDV) during labour, neonatal 
ZDV for 4–6 weeks and no breastfeeding.19
Mode of delivery and predictors of emergency caesarean 
section (EmCS) in WLWH compared with women from 
the general population (WGP) was assessed in a paper by 
Ørbæk et al.13 The number of WLWH who had a vaginal 
delivery increased over time, especially after the change 
in guidelines in 2007 offering vaginal delivery to WLWH 
with suppressed VLs. Compared with WGP more WLWH 
planned and delivered by planned caesarean section and 
they had a twofold higher risk of EmCS (figure 2). EmCS 
was predicted by age >40, African country of origin, 
asphyxia, delivery during the evening/night, preterm 
delivery and premature rupture of the membranes 
(PROM).13 A recent study showed that WLWH had more 
risk factors during pregnancy, including high body mass 
index (>25), smoking, prior perinatal deaths, prior 
caesarean section, viral hepatitis (chronic hepatitis B and 
C) and psychiatric disorders (DO993B1-5) and a higher 
risk of postpartum haemorrhage and EmCS than WGP.30 
The risk of most birth- related complications was similar 
between the groups. Children born to WLWH had a 
lower median birth weight and gestational age and were 
at higher risk of intrauterine growth retardation.30
It has been suggested that exposures to HIV and cART 
in utero may have adverse effects on infant development 
and growth.31–33 Using DHBC data, we compared anthro-
pometric outcomes in HEU children with a matched 
control group of children not exposed to HIV.34 HEU 
children were smaller (defined as weight- for- age z- score) 
and shorter (defined as length- for- age z- score) at birth, 
but this difference decreased with time and there was no 
significant difference between the groups at >18 months 
of age (figure 3). As the z- score already controls for age, 
gestational age (for children born <37 weeks gestation) 
and sex, these factors were not further controlled for. The 
absolute difference in weight and length between HEU 
and the control group children were relatively small, and 
was not considered to have a negative effect on the health 
and well- being of HEU children in early childhood.34
It has also been hypothesised that exposure to HIV 
and/or cART in utero or in the postnatal period may 
affect the development of the infant’s immune and other 
organ systems, resulting in higher morbidity rates among 
HEU compared with unexposed children.35–38 Our study 
investigating risk of in- hospital admission and use of anti-
biotics during the first 4 years of life among HEU chil-
dren, showed that HEU children had an increased risk 
of overall hospital admission compared with a matched 
Figure 2 Changes in mode of delivery during 2002–2014 
in (A) women living with HIV (WLWH) and (B) women in the 
general population (WGP)13 ECS, elective caesarean section; 
EmCS, emergency caesarean section.
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control group of unexposed children. This was mainly 
due to an increased risk of admission due to observation/
non- specific diagnosis, and there was no increased risk 
of admission due to infectious disease.39 Thus, the excess 
risk of admission among HEU children may be related to 
prophylactic treatment and/or HIV testing of the infant 
rather than somatic disease related to HIV and/or cART 
exposure.39
Strengths and limitations
The main strengths of the DHBC is the nationwide, 
population- based, prospective design including all 
WLWH who give birth in Denmark. Use of the unique 
PIN assigned to all Danes allows us to extract data for 
both the WLWH and their children in national registries. 
The use of registries ensures prospective, uniformly and 
neutral data collected on an individual level, restricting 
the methodological problems of loss to follow- up, selec-
tion bias and emigration. Moreover, linkage to the regis-
tries allow us to identify a population of controls who are 
matched on relevant variables. The main limitation of the 
DHBC is the relatively small number of children born to 
WLWH in Denmark. The DHBC is thus most useful for 
studies with frequently occurring outcomes.
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